6,000 Shares in Natera, Inc. $NTRA Bought by Encore Global Management LP

Posted by Francis Steltz on Jul 29th, 2026

Encore Global Management LP bought a new position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) in the first quarter, HoldingsChannel.com reports. The firm bought 6,000 shares of the medical research company’s stock, valued at approximately $1,200,000.

A number of other hedge funds also recently bought and sold shares of NTRA. Reflection Asset Management acquired a new position in shares of Natera during the 4th quarter worth about $29,000. Palladiem LLC bought a new stake in Natera during the 4th quarter valued at approximately $31,000. Bank of Jackson Hole Trust grew its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares during the last quarter. International Assets Investment Management LLC grew its holdings in Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in Natera in the 4th quarter worth approximately $39,000. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. The Goldman Sachs Group started coverage on Natera in a report on Friday, June 5th. They set a “neutral” rating and a $245.00 price target for the company. JPMorgan Chase & Co. boosted their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Guggenheim upped their target price on shares of Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Barclays cut their target price on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, June 24th. Finally, Royal Bank Of Canada assumed coverage on shares of Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Check Out Our Latest Analysis on Natera

Insider Buying and Selling at Natera

In related news, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the transaction, the director directly owned 4,250 shares of the company’s stock, valued at $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This represents a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 164,101 shares of company stock valued at $36,644,427 in the last quarter. 5.05% of the stock is currently owned by corporate insiders.

Natera Stock Down 2.3%

Natera stock opened at $252.22 on Wednesday. The business has a 50 day moving average price of $243.18 and a two-hundred day moving average price of $221.55. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The stock has a market cap of $36.12 billion, a price-to-earnings ratio of -154.74 and a beta of 1.51.

Natera Profile

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.